用于治疗胰腺癌的嵌合抗原受体T细胞疗法。
CAR T-cell therapy for pancreatic cancer.
作者信息
DeSelm Carl J, Tano Zachary E, Varghese Anna M, Adusumilli Prasad S
机构信息
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
J Surg Oncol. 2017 Jul;116(1):63-74. doi: 10.1002/jso.24627. Epub 2017 Mar 27.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
摘要
嵌合抗原受体（CAR）T细胞疗法利用基因工程技术将患者自身的T细胞重定向，以靶向癌细胞。在血液系统恶性肿瘤中取得的显著成果促使人们在胰腺癌等实体瘤中研究这种方法。复杂的肿瘤微环境、限制免疫反应的基质障碍以及T细胞上检查点阻断的表达构成了障碍。在此，我们总结了用CAR T细胞疗法靶向胰腺癌的机遇、挑战和知识现状。
相似文献
1
CAR T-cell therapy for pancreatic cancer.用于治疗胰腺癌的嵌合抗原受体T细胞疗法。
J Surg Oncol. 2017 Jul;116(1):63-74. doi: 10.1002/jso.24627. Epub 2017 Mar 27.
2
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.间皮素作为嵌合抗原受体修饰T细胞的抗癌治疗靶点。
Immunotherapy. 2016;8(4):449-60. doi: 10.2217/imt.16.4.
3
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.联合间皮素导向嵌合抗原受体 T 细胞和细胞因子武装溶瘤腺病毒治疗胰腺癌。
JCI Insight. 2018 Apr 5;3(7). doi: 10.1172/jci.insight.99573.
4
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.引入铰链区可改善嵌合抗原受体T细胞的扩增。
J Hematol Oncol. 2017 Mar 13;10(1):68. doi: 10.1186/s13045-017-0437-8.
5
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.分泌抗-FAP/抗-CD3 分子的间皮素 CAR T 细胞可有效靶向胰腺腺癌及其基质。
Clin Cancer Res. 2024 May 1;30(9):1859-1877. doi: 10.1158/1078-0432.CCR-23-3841.
6
Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.嵌合抗原受体 T 细胞疗法在胰腺癌中的应用：从研究到实践。
Med Oncol. 2018 May 4;35(6):84. doi: 10.1007/s12032-018-1145-0.
7
CAR T Cells Releasing IL-18 Convert to T-Bet FoxO1 Effectors that Exhibit Augmented Activity against Advanced Solid Tumors.嵌合抗原受体 T 细胞（CAR T 细胞）释放白细胞介素 18 可转化为 T 细胞特异性转录因子（T-Bet）FoxO1 效应物，对晚期实体瘤表现出增强的活性。
Cell Rep. 2017 Dec 12;21(11):3205-3219. doi: 10.1016/j.celrep.2017.11.063.
8
Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.质子放疗增强间皮素靶向嵌合抗原受体 T 细胞疗法在胰腺癌中的疗效。
Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2403002121. doi: 10.1073/pnas.2403002121. Epub 2024 Jul 24.
9
A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.间皮瘤嵌合抗原受体T细胞疗法的区域治疗方法：从小鼠模型到临床试验
Immunotherapy. 2016 May;8(5):491-4. doi: 10.2217/imt-2016-0008.
10
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.一种新型的抗前列腺干细胞抗原嵌合抗原受体在人源化胰腺癌小鼠模型中介导肿瘤破坏。
Hum Gene Ther. 2014 Dec;25(12):1003-12. doi: 10.1089/hum.2013.209.
引用本文的文献
1
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.实体瘤中CAR-T细胞疗法的进展：现状与未来方向
Cancers (Basel). 2025 Sep 3;17(17):2898. doi: 10.3390/cancers17172898.
2
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting.辅助治疗中基于免疫的胰腺癌治疗策略
Cancers (Basel). 2025 Apr 7;17(7):1246. doi: 10.3390/cancers17071246.
3
Pancreatic cancer: failures and hopes-a review of new promising treatment approaches.胰腺癌：失败与希望——新的有前景的治疗方法综述
Explor Target Antitumor Ther. 2025 Mar 18;6:1002299. doi: 10.37349/etat.2025.1002299. eCollection 2025.
4
Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.胰腺癌免疫治疗进展：新兴过继性细胞疗法简要综述
Cancers (Basel). 2025 Feb 9;17(4):589. doi: 10.3390/cancers17040589.
5
The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy.具有抗体依赖性安全策略的Claudin18.2靶向嵌合抗原受体T细胞疗法在晚期胰腺癌中的高效性
Mol Ther. 2025 Jan 10. doi: 10.1016/j.ymthe.2025.01.012.
6
Advancing Immunotherapy in Pancreatic Cancer.推进胰腺癌的免疫疗法。
Int J Mol Sci. 2024 Oct 28;25(21):11560. doi: 10.3390/ijms252111560.
7
Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions.转移性胰腺癌的系统治疗——现状与未来方向。
Curr Oncol. 2024 Sep 4;31(9):5206-5223. doi: 10.3390/curroncol31090385.
8
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.间皮素靶向嵌合抗原受体T细胞的区域递送可有效且安全地靶向小鼠的结直肠癌肝转移灶。
J Gastrointest Oncol. 2024 Feb 29;15(1):312-329. doi: 10.21037/jgo-24-25. Epub 2024 Feb 28.
9
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.胰腺癌肿瘤微环境是一个主要的治疗障碍和靶点。
Front Immunol. 2024 Feb 1;15:1287459. doi: 10.3389/fimmu.2024.1287459. eCollection 2024.
10
The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer.嵌合抗原受体（CAR）介导的细胞免疫疗法在胰腺癌临床应用中的潜力与前景。
J Adv Res. 2025 Jan;67:253-267. doi: 10.1016/j.jare.2024.01.014. Epub 2024 Jan 18.
本文引用的文献
1
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.嵌合抗原受体T细胞内在性程序性死亡蛋白1（PD-1）检查点阻断：实体瘤免疫治疗的二合一方法
Oncoimmunology. 2016 Dec 23;6(2):e1273302. doi: 10.1080/2162402X.2016.1273302. eCollection 2017.
2
Next frontiers in CAR T-cell therapy.嵌合抗原受体T细胞疗法的下一个前沿领域。
Mol Ther Oncolytics. 2016 Nov 30;3:16028. doi: 10.1038/mto.2016.28. eCollection 2016.
3
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.免疫细胞在胰腺癌中的作用：从 bench 到临床应用的最新综述。
Medicine (Baltimore). 2016 Dec;95(49):e5541. doi: 10.1097/MD.0000000000005541.
4
T-cell programming in pancreatic adenocarcinoma: a review.胰腺腺癌中的T细胞编程：综述
Cancer Gene Ther. 2017 Mar;24(3):106-113. doi: 10.1038/cgt.2016.66. Epub 2016 Dec 2.
5
Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.化疗对改善胰腺癌肿瘤微环境的临床影响。
World J Gastrointest Oncol. 2016 Nov 15;8(11):786-792. doi: 10.4251/wjgo.v8.i11.786.
6
Toxicity and management in CAR T-cell therapy.嵌合抗原受体 T 细胞疗法的毒性与管理。
Mol Ther Oncolytics. 2016 Apr 20;3:16011. doi: 10.1038/mto.2016.11. eCollection 2016.
7
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.综述：嵌合抗原受体（CAR）修饰T细胞的当前临床应用
Cytotherapy. 2016 Nov;18(11):1393-1409. doi: 10.1016/j.jcyt.2016.07.003. Epub 2016 Aug 31.
8
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.具有细胞内源性程序性死亡蛋白1（PD-1）检查点阻断功能的人嵌合抗原受体（CAR）T细胞可抵抗肿瘤介导的抑制作用。
J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.
9
Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.二甲双胍可提高胰腺导管腺癌合并糖尿病患者的生存率：一项倾向评分分析。
Am J Gastroenterol. 2016 Sep;111(9):1350-7. doi: 10.1038/ajg.2016.288. Epub 2016 Jul 19.
10
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.靶向膜黏蛋白MUC1的癌症相关Tn糖型的工程化嵌合抗原受体T细胞可控制腺癌。
Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.
Zotero 插件